Logo

ABSI

Absci Corporation

ABSI

Absci Corporation • NASDAQ
$3.18 ▲ 2.91% (+0.09)
Market Cap $478.18 M
52w High $6.33
52w Low $2.01
Dividend Yield 0%
P/E -3.49
Volume 1.46M
Outstanding Shares 150.37M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $378K ▼ $30.532M ▲ $-28.706M ▲ -7.594K% ▼ $-0.2 ▲ $-25.715M ▲
Q2-2025 $593K ▼ $11.528M ▼ $-30.569M ▼ -5.155K% ▼ $-0.24 ▼ $-28.393M ▼
Q1-2025 $1.179M ▲ $12.544M ▼ $-26.346M ▲ -2.235K% ▲ $-0.21 ▲ $-24.657M ▲
Q4-2024 $665K ▼ $13.462M ▼ $-28.983M ▼ -4.358K% ▼ $-0.25 ▼ $-25.14M ▼
Q3-2024 $1.701M $27.241M $-27.398M -1.611K% $-0.24 $-23.876M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $152.475M ▲ $244.992M ▲ $34.652M ▼ $210.34M ▲
Q2-2025 $117.458M ▼ $209.892M ▼ $36.519M ▲ $173.373M ▼
Q1-2025 $133.983M ▲ $232.447M ▲ $33.651M ▼ $198.796M ▲
Q4-2024 $112.425M ▼ $213.608M ▼ $34.475M ▲ $179.133M ▼
Q3-2024 $127.068M $235.231M $33.896M $201.335M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-28.706M ▲ $-25.031M ▼ $-63.702M ▼ $60.317M ▲ $-28.415M ▼ $-25.993M ▼
Q2-2025 $-30.569M ▼ $-16.873M ▲ $9.039M ▲ $-1.004M ▼ $-8.838M ▼ $-17.096M ▲
Q1-2025 $-26.346M ▲ $-21.839M ▼ $-15.044M ▼ $42.794M ▲ $5.911M ▲ $-21.864M ▼
Q4-2024 $-28.983M ▼ $-16.964M ▲ $19.043M ▲ $986K ▲ $3.065M ▲ $-16.987M ▲
Q3-2024 $-27.398M $-20.732M $14.806M $490K $-5.45M $-20.78M

Five-Year Company Overview

Income Statement

Income Statement Absci’s income statement looks like that of a very early‑stage biotech platform company: almost no recurring revenue yet, and steady, sizable losses. The company is spending far more on research, people, and infrastructure than it brings in from collaborations or services, so gross margins are negative and operating results are deeply in the red. The pattern over the last few years shows persistent losses rather than explosive deterioration. The gap between revenue and expenses remains wide, but it does not appear to be spiraling out of control. This fits a business that is still building technology and a drug pipeline rather than one that is commercializing products. For now, the income statement reflects investment mode, not a maturing revenue engine.

Balance Sheet

Balance Sheet The balance sheet shows a company with a solid equity base and relatively low debt, but with financial resources that have clearly come down since the IPO. Assets, including cash, have been drawn down over time to fund operations, while equity has gradually shrunk as losses accumulate. On the positive side, leverage is quite modest; the business does not appear to be heavily burdened with borrowings, which reduces financial risk. However, the cushion of cash and total assets is no longer as generous as it was just after going public, so the room for error over the next few years is smaller. Overall, the balance sheet remains clean but is gradually being consumed by ongoing losses.

Cash Flow

Cash Flow Cash flow is consistent with an R&D‑heavy biotech: money is flowing out of the business each year, mainly to cover operating costs, while cash coming in from customers or partners is still limited. Operating cash flow has been negative every year, and free cash flow is similarly negative, as capital spending is modest compared with operating outlays. The encouraging point is that the cash burn appears relatively stable rather than accelerating dramatically. Still, the company is not close to self‑funding. Its ability to keep going rests on its existing cash reserves plus any new funding or milestone payments it can secure. Management’s own guidance that current cash lasts into the middle of the decade underlines that additional capital or larger deals are likely needed before the business can stand on its own cash flows.

Competitive Edge

Competitive Edge Absci operates in a crowded and fast‑moving field: AI‑enabled drug discovery. Its positioning rests on being a full‑stack platform that blends generative AI with in‑house biology labs, rather than being just a software layer. That integrated approach, and the proprietary data it produces, form the core of its claimed competitive edge. Several factors strengthen its position: it can generate and test huge numbers of biological designs, it owns a growing private dataset that improves its models, and it has already attracted notable pharmaceutical partners and large potential deal values. At the same time, the company faces stiff competition from both specialized AI‑drug discovery firms and large pharmaceutical companies building their own AI capabilities. In practice, its competitive standing will be judged on whether it can keep signing high‑quality partners, move partnered and internal programs into the clinic efficiently, and demonstrate that its candidates perform better or move faster than those coming from traditional methods or rival platforms.

Innovation and R&D

Innovation and R&D Innovation is Absci’s core asset and main cost. The company’s Integrated Drug Creation platform combines generative AI that designs new biologic drugs with a high‑throughput lab that quickly tests them. This “lab‑in‑the‑loop” system creates a powerful feedback cycle: experiments generate proprietary data, the AI learns from that data, and the next designs, in theory, get better. Key differentiators include de novo antibody design (creating molecules from scratch), the ability to go after difficult or previously “undruggable” targets, and proprietary cell and assay technologies that let it generate very large, high‑quality datasets. These capabilities underpin a pipeline of internal programs across hair loss, inflammatory diseases, oncology, and other areas. However, the platform is still in an early validation phase. The R&D strategy is ambitious, but most value will only be proven as internal drugs produce strong clinical data and partnered projects advance. Until then, R&D is more of a promise than a fully realized asset, even if the technology foundation appears sophisticated and differentiated.

Summary

Absci is an early‑stage, platform‑driven biotech company trying to use generative AI and synthetic biology to redesign how biologic drugs are discovered. Financially, it is still pre‑commercial: revenues are minimal, losses are substantial, and cash is being steadily drawn down to fund R&D and platform development. The balance sheet remains relatively clean, with low debt, but its resources are finite and trending lower as operations consume cash. Strategically, the company’s strength lies in its integrated AI‑plus‑wet‑lab platform, large proprietary datasets, and a set of high‑profile pharma and tech partnerships. These create a credible competitive story in a hot but crowded space. The key uncertainties are execution and validation: Absci must translate its technology into successful clinical outcomes, durable partnerships, and eventually recurring revenue, all while managing its cash runway. Overall, this is a high‑risk, high‑uncertainty profile typical of cutting‑edge biotech platforms: strong innovation and notable partners on one side, but ongoing losses, dependence on external funding, and the need for clinical proof on the other. Observers may want to focus on cash usage, new or expanded collaborations, and concrete milestones from the internal pipeline as primary indicators of progress.

NEWS

November 12, 2025 · 4:05 PM UTC

Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

Read more

October 29, 2025 · 4:05 PM UTC

Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025

Read more

October 27, 2025 · 8:00 AM UTC

Absci to Participate in Upcoming Investor Conferences

Read more

October 15, 2025 · 8:00 AM UTC

Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial

Read more

September 11, 2025 · 8:00 AM UTC

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

Read more